NCT04202263

Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: State University of New York - Downstate Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Adults with known respiratory allergy/asthma with known skin test sensitization will undergo repeat skin prick testing at 4 areas of both arms (bilateral forearms, bilateral upper arms). Each site will be challenged with up to three known allergens, saline and histamine controls. Mean wheal diameter after 20 minutes challenge will be determined. This is followed by placement of minocycline cream (0%, 1%, 2%, 3%), placed in randomized fashion at each of 1 of 4 skin test sites. Measurement of subsequent wheal diameter will be done at 30 minutes, 60 minutes and 24 hours.

Detailed description

Adults with known respiratory allergy/asthma with known skin test sensitization will undergo repeat skin prick testing at 4 areas of both arms (bilateral forearms, bilateral upper arms). Each site will be challenged with up to three known allergens, saline and histamine controls. Mean wheal diameter after 20 minutes challenge will be determined. This is followed by placement of minocycline cream (0%, 1%, 2%, 3%), placed in randomized fashion at each of 1 of 4 skin test sites. Measurement of subsequent wheal diameter will be done at 30 minutes, 60 minutes and 24 hours. In addition, itch assessment at each site will be done at baseline, 30 minutes, 60 minutes and 24 hours using VAS and questionnaire.

Conditions

• Allergic Rhinitis
• Asthma

Interventions

Type	Name	Description
DRUG	Minocycline Topical	Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
DRUG	Placebos	Placement of minocycline cream 0%

Timeline

• Start date: 2019-09-26
• Primary completion: 2023-09-25
• Completion: 2023-09-25
• First posted: 2019-12-17
• Last updated: 2021-10-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study